• Sosei Group Corp., of Tokyo, said QVA149 (indacaterol maleate/glycopyrronium bromide) met the primary endpoint in its fifth Phase III trial, which enrolled more than 2,000 subjects. Patients treated with once-daily QVA149 for 64 weeks demonstrated a clinically meaningful and statistically significant lower rate of moderate-to-severe chronic obstructive pulmonary disease exacerbations compared with those treated with glycopyrronium 50 mcg. The SPARK trial is the final study intended for initial regulatory filings of QVA149 in Europe and Japan, which are expected later this year. U.S. filing is expected at the end of 2014. Novartis AG, of Basel, Switzerland, is responsible for development and commercialization of the combination product under a 2005 licensing agreement. (See BioWorld Today, May 18, 2012.)